Immunological Mechanisms Related to Clinical Responsiveness Differ Between Methotrexate Monotherapy and Methotrexate and anti-TNFá Co-Treatment in Rheumatoid Arthritis
Friday, November 20, 2009
Theo van den Broek, M.D.
Research Fellow The University of Arizona Arthritis Center
Objectives Participants should be able to: Understand that the anti-TNFá treatment is not merely focused on TNFá suppression Recognize that the clinical response by Methotrexate treatment or when in combination with an anti-TNFá agent is due to different mechanisms Understand that Methotrexate treatment involves aspects of immune tolerance and regulation while anti-TNFá/Methotrexate treatment downregulates the pro-inflammatory aspects of Teff and APC